Dr. Cookson on SUO educational initiatives for 2022
“We're really moving into not just these annual meetings, but we're going to have some programs throughout the year that will be targeted towards…really important, impactful research that comes out,” says Michael S. Cookson, MD, MMHC, FACS.
In this video, the Society of Urologic Oncology’s (SUO) Past President Michael S. Cookson, MD, MMHC, FACS, discusses his impressions of the 2021 SUO Annual Meeting and what educational initiatives are taking place in 2022 leading up to next year’s meeting. Cookson is a professor and the Donald D. Albers endowed chair in urology at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
